X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT LTD. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT LTD. GLENMARK PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 13.5 16.3 83.0% View Chart
P/BV x 3.8 1.7 228.1% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
WOCKHARDT LTD.
Mar-16
GLENMARK PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,2622,000 63.1%   
Low Rs672706 95.1%   
Sales per share (Unadj.) Rs270.6403.7 67.0%  
Earnings per share (Unadj.) Rs24.929.5 84.4%  
Cash flow per share (Unadj.) Rs34.442.4 81.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs151.3323.4 46.8%  
Shares outstanding (eoy) m282.16110.51 255.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.63.4 106.6%   
Avg P/E ratio x38.945.9 84.6%  
P/CF ratio (eoy) x28.131.9 88.0%  
Price / Book Value ratio x6.44.2 152.7%  
Dividend payout %8.00-   
Avg Mkt Cap Rs m272,778149,509 182.4%   
No. of employees `00010.07.4 135.9%   
Total wages/salary Rs m13,7829,443 145.9%   
Avg. sales/employee Rs Th7,614.96,048.6 125.9%   
Avg. wages/employee Rs Th1,374.81,280.2 107.4%   
Avg. net profit/employee Rs Th700.2441.5 158.6%   
INCOME DATA
Net Sales Rs m76,34044,614 171.1%  
Other income Rs m356970 36.7%   
Total revenues Rs m76,69645,584 168.3%   
Gross profit Rs m14,1725,038 281.3%  
Depreciation Rs m2,6911,426 188.8%   
Interest Rs m1,7891,012 176.8%   
Profit before tax Rs m10,0483,570 281.4%   
Minority Interest Rs m0-65 0.0%   
Prior Period Items Rs m06 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,028255 1,188.5%   
Profit after tax Rs m7,0193,257 215.5%  
Gross profit margin %18.611.3 164.4%  
Effective tax rate %30.17.1 422.3%   
Net profit margin %9.27.3 126.0%  
BALANCE SHEET DATA
Current assets Rs m59,09639,906 148.1%   
Current liabilities Rs m40,01818,423 217.2%   
Net working cap to sales %25.048.2 51.9%  
Current ratio x1.52.2 68.2%  
Inventory Days Days7590 83.1%  
Debtors Days Days11998 121.3%  
Net fixed assets Rs m39,07535,832 109.1%   
Share capital Rs m282553 51.1%   
"Free" reserves Rs m30,28130,370 99.7%   
Net worth Rs m42,70335,739 119.5%   
Long term debt Rs m24,87316,542 150.4%   
Total assets Rs m111,02679,522 139.6%  
Interest coverage x6.64.5 146.1%   
Debt to equity ratio x0.60.5 125.8%  
Sales to assets ratio x0.70.6 122.6%   
Return on assets %7.95.4 147.8%  
Return on equity %16.49.1 180.4%  
Return on capital %17.58.7 202.4%  
Exports to sales %43.311.6 373.0%   
Imports to sales %7.44.5 166.6%   
Exports (fob) Rs m33,0445,177 638.3%   
Imports (cif) Rs m5,6721,990 285.0%   
Fx inflow Rs m36,9457,589 486.8%   
Fx outflow Rs m61,0662,878 2,121.5%   
Net fx Rs m-24,1224,711 -512.1%   
CASH FLOW
From Operations Rs m3,449716 481.6%  
From Investments Rs m-8,802-8,182 107.6%  
From Financial Activity Rs m6,9862,543 274.8%  
Net Cashflow Rs m934-4,923 -19.0%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - BIOCON LTD COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS